Shore Capital Reaffirms “House Stock” Rating for Destiny Pharma (LON:DEST)

Shore Capital restated their house stock rating on shares of Destiny Pharma (LON:DEST) in a report published on Monday morning, MarketBeat.com reports.

Destiny Pharma Price Performance

DEST stock opened at GBX 4.25 ($0.06) on Monday. Destiny Pharma has a 1-year low of GBX 2 ($0.03) and a 1-year high of GBX 84 ($1.09). The business has a fifty day moving average price of GBX 12.03 and a 200-day moving average price of GBX 29.93. The stock has a market capitalization of £4.05 million, a P/E ratio of -70.83 and a beta of 0.31.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.